


Georgia

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline		2009	2009 2012		2015			2018
International units	Factor VIII	0.45	A	1.68	A	1.93	A	2.29
per capita	Factor IX	0.10	A	0.22	•	0.21	A	0.40
Organisation	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
of care	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group					Yes		Yes
	Number of groups in decision-making on haemophilia care	0		0	A	2	_	3
	Number of groups choosing haemophilia treatment products	0		0	A	3		3
	National Tender for procurement of factor concentrates					Yes		Yes
Treatment	Home Treatment	Yes		Yes		Yes		Yes
regimens	% of people with haemophilia using home treatment	76-100%		76-100%		76-100%		76-100%
	Treatment delivered to the patient's home	No		No		No		Some
	Prophylaxis treatment availability	No		No		No	_	Some
	Children currently on prophy (%)	0		0		0		26-50%
	Adults currently on prophy (%)	0		0		0		1-25%
	Access to ITI (% of people with inhibitors)	0		0		1-25%		1-25%
Access to	Emergency medicine and acute surgery					Yes		Yes
specialist services	Paediatrics					Yes		Yes
	Infectious disease specialists (especially HIV)					Sometimes	•	Never
	Hepatology					Sometimes	•	Never
	Rheumatology					Never		Never
	Orthopaedics					Yes	•	Sometimes
	Physiotherapy					Yes		Yes
	Dentistry					Sometimes	•	Never
	Obstetrics and Gynaecology					Sometimes	•	Never
	Genetics					Never		Never
	Social and psychological support					Sometimes	•	Never
	Pain management					Yes		Yes
	General surgery					Yes	•	Sometimes
	Urology					Sometimes		Sometimes
Share of Expected	Haemophilia A	53%	A	62%	A	68%	A	73%
Bleeding Disorder	Haemophilia B	34%	A	35%	A	41%	_	48%
Prevalence	von Willebrand Disease	0%	A	1%	A	1%	A	1%
Haemophilia	Pasma-derived factor concentrate	Always		Always		Always		Always
replacement	Recombinant factor concentrate	Never		Never		Never	_	Rarely
therapy	Plasma	Rarely						Rarely
	Cryoprecipitate	Rarely				Rarely		Rarely
VWD replacement	Plasma-derived factor concentrate							Rarely
therapy	DDAVP							Rarely
	Plasma					Always		Always
	Cryoprecipitate							Always